PCN25 COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL AS A SECOND- OR THIRD-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN KOREA
Nov 1, 2010, 00:00 AM
10.1016/S1098-3015(11)73117-5
https://www.valueinhealthjournal.com/article/S1098-3015(11)73117-5/fulltext
Section Title :
RESEARCH POSTER ABSTRACTS
Section Order :
1274
First Page :
A514
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)73117-5&doi=10.1016/S1098-3015(11)73117-5